

Supplementary material

Table 1 Search terms

OVID Medline
1. Collaborative care.mp.
2. integrat* care.mp.
3. "Delivery of Health Care, Integrated"/
4. Psychotherapy/ec
5. Mood Disorders/th
6. Depressive Disorder/th
7. Depressive Disorder, Major/th
8. talking therap*.mp.
9. liaison service*.mp.
10. liaison work*.mp.
11. IAPT.mp.
12. Improving access to psychological therap*.mp.
13. Community Mental Health Centers/ec
14. Cognitive Therapy/
15. Anxiety/th [Therapy]
16. Bipolar Disorder/rh [Rehabilitation]
17. Bipolar Disorder/th [Therapy]
18. Complementary Therapies/ec [Economics]
19. Depression/th [Therapy]
20. Depressive Disorder/rh [Rehabilitation]
21. Depressive Disorder, Treatment-Resistant/th [Therapy]
22. Mental Disorders/th [Therapy]
23. Primary Health Care/ec [Economics]
24. Psychotherapy/mt [Methods]
25. Psychotherapy, Brief/ec [Economics]
26. Psychotherapy, Group/ec [Economics]
27. Psychotic Disorders/th [Therapy]
28. Psychotic Disorders/rh [Rehabilitation]
29. Schizophrenia/rh [Rehabilitation]

30. Schizophrenia/th [Therapy]
31. *Depression/pc [Prevention & Control]
32. *Schizophrenia/pc [Prevention & Control]
33. community mental health team.mp.
34. family therapy/ and cost effectiveness analysis/
35. family work.mp.
36. (mental disease and disease management).mp.
37. patient counseling.mp.
38. psychotherapy/ and cost effectiveness analysis/
39. telecare.mp.
40. Cognitive Behavior Therapy.mp.
41. Metacognitive group training.mp.
42. psychosocial rehabilitation.mp.
43. Bipolar Disorder/
44. Psychotic Disorders/
45. Schizophrenia/
46. Economics/
47. exp "costs and cost analysis"/
48. Economics, Dental/
49. exp economics, hospital/
50. Economics, Medical/
51. Economics, Nursing/
52. Economics, Pharmaceutical/
53. (economic\$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic\$).ti,ab.
54. (expenditure\$ not energy).ti,ab.
55. value for money.ti,ab.
56. budget\$.ti,ab.
57. or/46-56
58. ((energy or oxygen) adj cost).ti,ab.
59. (metabolic adj cost).ti,ab.
60. ((energy or oxygen) adj expenditure).ti,ab.
61. or/58-60

62. 57 not 61
63. or/1-42
64. or/43-45
65. 62 and 63 and 64
66. (letter or editorial or note or news or congresses or case reports).pt.
67. 65 not 66
68. limit 67 to (english language and humans and yr="2017 - 2019")
EMBASE
1. cognitive therapy/
2. community mental health team.mp.
3. family therapy/ and cost effectiveness analysis/
4. family work.mp.
5. *mental disease/dm [Disease Management]
6. *patient counseling/
7. psychotherapy/ and cost effectiveness analysis/
8. telecare.mp.
9. peer support.mp.
10. *group therapy/
11. or/1-10
12. schizophrenia/
13. bipolar disorder/
14. Psychotic Disorders/
15. or/12-14
16. Health Economics/
17. exp Economic Evaluation/
18. exp Health Care Cost/
19. pharmacoeconomics/
20. or/16-19
21. (econom\$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic\$).ti,ab.
22. (expenditure\$ not energy).ti,ab.
23. (value adj2 money).ti,ab.
24. budget\$.ti,ab.

25. or/21-24
26. 20 or 25
27. (metabolic adj cost).ti,ab.
28. ((energy or oxygen) adj cost).ti,ab.
29. ((energy or oxygen) adj expenditure).ti,ab.
30. or/27-29
31. 26 not 30
32. 11 and 15 and 31
33. (letter or editorial or note or news or congresses or case reports).pt.
34. 32 not 33
34. limit 33 to (human and english language and yr="2017 - 2019")
PsychINFO
1. *Cognitive Behavior Therapy/
2. *family therapy/
3. Metacognitive group training.mp.
4. *Psychosocial Rehabilitation/
5. Collaborative care.mp.
6. integrat* care.mp.
7. talking therap*.mp.
8. liaison service*.mp.
9. liaison work*.mp.
10. IAPT.mp.
11. Improving access to psychological therap*.mp.
12. *Bipolar disorder/
13. *Schizophrenia/
14. exp Psychosis/
15. "costs and cost analysis"/
16. "Cost Containment"/
17. (economic adj2 evaluation\$).ti,ab.
18. (economic adj2 analy\$).ti,ab.
19. (economic adj2 (study or studies)).ti,ab.
20. (cost adj2 evaluation\$).ti,ab.

21. (cost adj2 analy\$).ti,ab.
22. (cost adj2 (study or studies)).ti,ab.
23. (cost adj2 effective\$).ti,ab.
24. (cost adj2 benefit\$).ti,ab.
25. (cost adj2 utili\$).ti,ab.
26. (cost adj2 minimi\$).ti,ab.
27. (cost adj2 consequence\$).ti,ab.
28. (cost adj2 comparison\$).ti,ab.
29. (cost adj2 identificat\$).ti,ab.
30. (pharmacoeconomic\$ or pharmaco-economic\$).ti,ab.
31. (task adj2 cost\$).ti,ab,id.
32. (switch\$ adj2 cost\$).ti,ab,id.
33. (metabolic adj cost).ti,ab,id.
34. ((energy or oxygen) adj cost).ti,ab,id.
35. ((energy or oxygen) adj expenditure).ti,ab,id.
36. or/1-11
37. or/12-14
38. or/15-30
39. or/31-35
40. 36 and 37 and 38
41. 40 not 39
42. dissertation abstract.pt.
43. (letter or editorial).dt.
44. 42 or 43
45. 41 not 44
46. limit 45 to (human and english language and yr="2017 - 2019")

Table 2 CHEERS checklist

Key: 0 = Not reported, 1= Partly reported, 2 = Well reported, - = Not applicable.

Section/item	No	Recommendation	Haddock et al. (2003)	Lam et al. (2005)	Barton et al. (2009)	McCrone et al. (2010)	Patel et al. (2010)	van der Gaag et al. (2011)	Crawford et al. (2012)	Karow et al. (2012)	Hastrup et al. (2013)	Priebe et al. (2016)	Rosenheck et al. (2016)	Camacho et al. (2017)
Title and abstract														
Title	1	Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared.	0	2	2	2	2	2	2	2	2	2	2	2
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	1	1	2	2	1	2	2	2	1	1	2	2
Introduction														
Background and objectives	3	Provide an explicit statement of the broader context for the study.	2	2	2	2	2	2	2	2	2	2	2	2
		Present the study question and its relevance for health policy or practice decisions.	2	2	1	2	2	2	2	2	2	2	2	2
Methods														
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	2	2	2	2	2	2	2	2	2	2	2	2
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	2	2	2	2	2	2	2	2	2	2	2	2
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	2	0	2	2	2	2	2	2	2	2	1	2
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	1	1	1	1	1	1	2	2	1	2	1	2
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	2	2	2	2	2	2	2	2	2	2	2	2
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	2	0	-	2	-	1	2	-	2	-	0	2
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	2	1	2	2	2	2	2	2	1	2	2	2
Measurement of effectiveness	11a	<i>Single study-based estimates:</i> Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	1	1	1	1	1	1	2	1	1	2	2	2
	11b	<i>Synthesis-based estimates:</i> Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	-	-	-	-	-	-	-	-	-	-	-	-
Measurement and valuation of preference-	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	-	-	2	-	-	-	2	2	-	2	-	2

based outcomes														
Estimating resources and costs	13a	<i>Single study-based economic evaluation:</i> Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	2	2	2	2	2	2	2	2	2	2	2	2
	13b	<i>Model-based economic evaluation:</i> Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	-	-	-	-	-	-	-	-	-	-	-	2
Currency, price date, and conversion	14	Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.	2	1	2	2	2	2	2	2	2	2	2	2
Choice of model	15	Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended.	-	-	-	-	-	-	-	-	-	-	-	2
Assumptions	16	Describe all structural or other assumptions underpinning the decision-analytical model.	-	-	-	-	-	-	-	-	-	-	-	2
Analytical methods	17	Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.	2	2	2	2	2	2	2	2	2	2	2	2
Results														
Study parameters	18	Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.	2	1	1	1	1	1	2	1	1	1	1	1
Incremental costs and outcomes	19	For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.	2	1	1	1	2	1	2	1	2	1	2	2
Characterising uncertainty	20a	<i>Single study-based economic evaluation:</i> Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact of methodological assumptions (such as discount rate, study perspective).	2	2	2	2	2	2	2	2	2	2	2	2
	20b	<i>Model-based economic evaluation:</i> Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	-	-	-	-	-	-	-	-	-	-	-	2
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	1	1	1	2	1	1	2	1	1	2	0	2
Discussion														

Study findings, limitations, generalisability, and current knowledge	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.	1	1	2	2	2	2	2	2	1	2	2	1	2
Other															
Source of funding	23	Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	2	2	2	2	2	2	2	2	2	0	2	2	2
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	0	0	2	0	2	0	0	2	0	0	0	2	2

Note that study reporting will vary according to journal requirements. Additionally, all studies were conducted alongside randomised controlled trials and therefore items not reported may have been reported elsewhere.